Paper20100967
Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
Friedel G and 15 others. J Clin Oncol, 2010. Cited by 65 papers, by iCite.
Cite this record
ConductScience Library. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. Papers, record 20100967. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20100967
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
- PubMed
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Dose Fractionation, Radiation | Major topic |
| Lung Neoplasms | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Thoracotomy | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Carboplatin | |
| Combined Modality Therapy | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoadjuvant Therapy | |
| Neoplasm Staging | |
| Paclitaxel | |
| Prognosis | |
| Remission Induction | |
| Survival Rate | |
| Treatment Outcome | |
| Young Adult |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 21205753 | Trimodality therapy for locally advanced non-small-cell lung cancer: a curative approach. | https://conductscience.org/library/papers/21205753 |
Source PubMed
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39199656 | Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39199656 | PubMed |
| 36975452 | Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options. | Curr Oncol | 2023 | https://conductscience.org/library/papers/36975452 | PubMed |
| 36672363 | VATS versus Open Lobectomy following Induction Therapy for Stage III NSCLC: A Propensity Score-Matched Analysis. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36672363 | PubMed |
| 34776459 | Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy. | Ann Thorac Cardiovasc Surg | 2022 | https://conductscience.org/library/papers/34776459 | PubMed |
| 34104514 | Evaluation of prognostic factors in lung cancers with surgical complete response after induction treatment. | Turk Gogus Kalp Damar Cerrahisi Derg | 2021 | https://conductscience.org/library/papers/34104514 | PubMed |
| 33449266 | Survival analysis of pathological complete response of locally advanced lung cancer after neoadjuvant treatment. | Gen Thorac Cardiovasc Surg | 2021 | https://conductscience.org/library/papers/33449266 | PubMed |
| 33265905 | Prognostic Factors and Long-Term Survival in Locally Advanced NSCLC with Pathological Complete Response after Surgical Resection Following Neoadjuvant Therapy. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33265905 | PubMed |
| 32722386 | Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32722386 | PubMed |
| 32642168 | Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery. | J Thorac Dis | 2020 | https://conductscience.org/library/papers/32642168 | PubMed |
| 30778734 | Keys to successful induction chemoradiotherapy followed by surgery for stage III/N2 non-small cell lung cancer. | Surg Today | 2019 | https://conductscience.org/library/papers/30778734 | PubMed |
| 30725275 | Non-small cell lung cancer with pathological complete response: predictive factors and surgical outcomes. | Gen Thorac Cardiovasc Surg | 2019 | https://conductscience.org/library/papers/30725275 | PubMed |
| 30626407 | Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity. | J Cardiothorac Surg | 2019 | https://conductscience.org/library/papers/30626407 | PubMed |
| 30083866 | Surgical outcomes and complications of pneumonectomy after induction therapy for non-small cell lung cancer. | Gen Thorac Cardiovasc Surg | 2018 | https://conductscience.org/library/papers/30083866 | PubMed |
| 29997942 | Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer. | J Thorac Dis | 2018 | https://conductscience.org/library/papers/29997942 | PubMed |
| 28932596 | Examining the ınterval between radiation therapy and surgery in trimodality therapy: Try Tri Again. | J Thorac Dis | 2017 | https://conductscience.org/library/papers/28932596 | PubMed |
| 28426673 | Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC. | PLoS One | 2017 | https://conductscience.org/library/papers/28426673 | PubMed |
| 27358568 | Effectiveness of a thoracic multidisciplinary clinic in the treatment of stage III non-small-cell lung cancer. | J Multidiscip Healthc | 2016 | https://conductscience.org/library/papers/27358568 | PubMed |
| 26846419 | Preceding bronchial cutting for exposure of the pulmonary artery buried in scar tissue after chemoradiotherapy. | Gen Thorac Cardiovasc Surg | 2017 | https://conductscience.org/library/papers/26846419 | PubMed |
| 26410162 | Pneumonectomy for Clinical Stage IIIA Non-Small Cell Lung Cancer: The Effect of Neoadjuvant Therapy. | Ann Thorac Surg | 2016 | https://conductscience.org/library/papers/26410162 | PubMed |
| 26319488 | The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis. | Ann Thorac Surg | 2015 | https://conductscience.org/library/papers/26319488 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20100967
GET https://conductscience.org/api/papers/v1/20100967/cited_by?page=2